QIPT
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Forward P/E is unsustainable relative to current earnings trajectory.
- Low P/S ratio
- Extreme Forward P/E (182.50)
- P/B of 1.59 with negative ROE
Growth is present in top-line but absent in bottom-line consistency.
- Strong revenue growth (32%)
- Recent Q/Q EPS growth (+75%)
- Inability to convert revenue growth into net profit
Long-term trend is negative despite short-term volatility.
- Recent 1Y price recovery
- 5Y change of -44.7%
- Chronic earnings misses
Deterministic health scores indicate a weak financial foundation.
- Debt/Equity is moderate (1.02)
- Piotroski F-Score 3/9
- Quick Ratio 0.60
Non-dividend paying growth/turnaround play.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for QIPT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
QIPT
Quipt Home Medical Corp
Primary
|
-44.7% | -42.7% | +56.0% | +34.2% | +1.1% | 0.0% |
|
ACH
Accendra Health, Inc.
Peer
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
|
HRTX
Heron Therapeutics, Inc.
Peer
|
-94.8% | -68.8% | -53.1% | -33.4% | -12.1% | +6.6% |
|
QTRX
Quanterix Corporation
Peer
|
-94.1% | -71.3% | -32.0% | -40.3% | -22.6% | +4.2% |
|
DERM
Journey Medical Corporation
Peer
|
-50.0% | +251.1% | -28.9% | -34.4% | -38.3% | +5.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
QIPT
Quipt Home Medical Corp
|
BEARISH | $162.3M | - | -9.3% | -4.0% | $3.65 | |
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | Compare |
|
HRTX
Heron Therapeutics, Inc.
|
BEARISH | $160.82M | - | -% | -13.0% | $0.85 | Compare |
|
QTRX
Quanterix Corporation
|
BEARISH | $164.29M | - | -34.2% | -77.1% | $3.5 | Compare |
|
DERM
Journey Medical Corporation
|
BEARISH | $164.62M | - | -44.0% | -18.5% | $4.95 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-05 | Crawford (Gregory John) | Director of Issuer | Option Exercise | 581,000 | $630,966 |
| 2025-12-05 | Crawford (Gregory John) | Director of Issuer | Other at price 1.09 per share. | 2,500 | $2,715 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning QIPT from our newsroom.